BioElectronics Investor Updates
Thursday, August 7, 2014
ActiPatch® Testimonial Video
We’ve compiled a video of testimonials from our “Try It and Tell Us” Facebook Social Media Program in the United Kingdom and Ireland.
Please visit http://youtu.be/Ngsht0VJbWU to view the video.
The “Try It & Tell Us” sample program for United Kingdom and Ireland residents is working well with thousands of 7-day ActiPatch® Therapy samples already shipped. For first-hand testimonials from the consumers visit www.actipatch.com/testimonials or www.facebook.com/ActiPatch to see what people in the UK and Ireland are saying about the product.
Try & Tell 7-Day Sample Survey Pain Data Results Summary
BioElectronics has established a free 7-day sample trial for its 30-day retail device. Approximately one week after the estimated delivery date of the sample, the participants are sent a Constant Contact survey containing both clinical and commercial purchase questions; please see Exhibit “A”. In total, 3,500 emails were sent out with a response rate of 15% or 515 surveys. Exhibit “B” indicates that there is little concern with non-response bias.
Musculoskeletal pain is wide spread in society, negatively affects the quality of life and is currently inadequately treated. Survey responders reported an existing baseline VAS pain score of 8.4, indicating minimal relief from existing therapies. The results from this study indicate that it is an effective pain therapy for osteoarthritis, rheumatoid arthritis, fibromyalgia and chronic back pain. Positive responders (77%) had an average pain reduction of 52%, which is clinically significant. By cause:
- Osteoarthritis response rate was 85% with a 4.5 VAS (55%) pain reduction
- Rheumatoid arthritis response rate was 84% with a 4.4 VAS (50%) pain reduction
- Fibromyalgia response rate was 72% with a 4.4 VAS point (49%) reduction
- Chronic back pain response rate was 75% with a 4.2 VAS point (50%) reduction
Customer responses on intent to purchase were 58% YES, 22% Maybe, and 20% NO.
Exhibit A – Survey Questions
1 – Please rate your experience using the ActiPatch.
1- Well Below Average 2-Below Average 3-Above Average 4-Above Average 5-Well Above Average
2. Where is your pain?
Other: Please specify
3. Do you know what causes your pain?
Other: Please specify
4. How long have you experienced this pain?
Less than 3 months
3 – 6 months
Greater than 6 months
5. On a scale from 0-10, please rate the amount of pain you experienced BEFORE you used ActiPatch. 0
being no pain and 10 being severe.
6. On a scale from 0-10, please rate the amount of pain you experienced AFTER you used ActiPatch. 0
being no pain and 10 being severe.
7. How long did it take for you to notice pain relief from using ActiPatch?
1-2 days 3 days 4 days 5 days 6 days 7 days
(Note: The device has 7 days of use.)
8. How likely is it that you would recommend the ActiPatch to a friend or family member?
9. Which category describes your age?
18 – 24
25 – 34
35 – 44
45 – 54
55 – 64
65 or older
Exhibit B – Survey Data Non Response Bias
Non-response bias: One major issue with surveys is non-response bias, i.e., persons who respond are different from those who do not respond. If so, then using only the responses to estimate the views of the total population of sampled respondents can yield biased results. For example, people who respond often feel more strongly on an issue or have some major reason for voicing their views with the researcher. One method of overcoming this non-response bias issue is to analyze the results over successive “waves” of responses under the assumption that persons who respond in later waves, e.g., after a second reminder, are similar to the non-respondents. In a classic paper by Armstrong and Overton (Journal of Marketing, 1977), it was shown that by extrapolating any trends in the data over the two waves it was possible to predict the bias correctly in the third wave 89% of the time. They conclude that this method is the best method for determining non-response bias from just the obtained responses. We use this approach to look at the non-response bias (or lack thereof) in our survey.
A total of 1550 ActiPatch sample users were emailed, data collected (first wave) and 5 days later sent a second email to elicit further responses (second wave). Total responses were 155, 113 in the first wave and 42 in the second wave.
1. There was no statistical (or meaningful) difference in initial pain level across the two waves
2. There was no statistical difference in improvement across the two waves although there was a slight decrease in improvement from 41% to 40%
3. There were a slightly different number of people indicating no improvement across the two waves. There was 18% for the first wave and 25% for the second wave.
There is no bias in terms of initial pain levels. There is a slight bias in terms of people responding in getting improvement from the product. In fact, we noted that some of the first wave respondents indicated that they got negative improvement—while this did not occur in the second wave. Instead, some of the second waves were more likely to report no improvement. Thus a more conservative estimate of how many people get improvement would be somewhere between 82 and 75% (average obtained from 351 responses 77%).
Conclusion: The data from this two wave survey shows there is little concern with non-response bias.
UK Boots PR Update
A Daisy Chain Dream – a blogger in the UK reviewed the ActiPatch
See the bog here: http://www.adaisychaindream.com/on-trial-actipatch/
Erisea-Magazine – a blogger in the UK reviewed the ActiPatch
See the bog here: http://erisea-mag.com/the-actipatch/
A popular sport UK blogger How Iron Man Are Made mentioned ActiPatch in an ‘Aching’ feature.
BioElectronics is currently exhibiting at the 2014 FIME International Medical Trade Fair in Miami, FL. FIME is the largest International Medical Trade Fair and Congress in the United States. The annual event is a purchasing show, drawing conventional distributor networks, group purchasing organizations, integrated delivery networks, hospitals, imaging centers, private practice facilities, and HME / DME providers. The dynamic attendee base is key to penetrating and navigating around complicated medical distribution channels and networks.
BioElectronics Booth #: 1785
Please visit http://www.bielcorp.com/fime-tradeshow-2014/ for more information.
BioElectronics Social Media
Connect with us through social media to receive company updates along with other valuable information:
Next Company Update: Thursday, September 4, 2014
To receive investor updates via e-mail, please contact us at IR@bielcorp.com with your name and e-mail address. Updates are posted every other Thursday. Thank you for your support!